By Scientia Professor Gregory John Dore

Conference Papers

Thompson AJ; Roberts S; Strasser S; Bollipo S; Sloss A; Wenman J; Cheng W; Angus P; Levy M; Mitchell J; Sievert W; Leggett B; Dore G; George J, 2013, 'IL28B genotype frequency in Australian patients with genotype 2/3 HCV differs from that observed in genotype 1 HCV: Interim analysis of the GUIDE study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 173 - 173, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000324106900357&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Jacobson IM; Dore GJ; Foster G; Fried MW; Radu MN; Rafalskiy VV; Moroz L; Craxiag A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Kalmeijer R; Beumont-Mauviel M, 2013, 'Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, FL, Orlando, pp. S374 - S374, presented at Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT), FL, Orlando, 18 May 2013 - 21 May 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000322997202152&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hajarizadeh B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Grady B; Schinkel J; Maher L; Hellard M; Lloyd AR; Prins M; Grebely J; Dore GJ; Group OBOTIS, 2013, '1157 EARLY HCVRNA DYNAMICS AND FACTORS ASSOCIATED WITH HIGH EARLY HCVRNA LEVEL DURING ACUTE HCV INFECTION', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s470 - s471, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/s0168-8278(13)61158-7

Dore GJ; Lawitz E; H'ezode C; Shafran S; Ramji A; Tatum H; Taliani G; Tran A; Brunetto M; Zaltron S; Strasser S; Weis N; Ghesquiere W; Lee S; Larrey D; Pol S; Harley H; George J; Fung S; de L'edinghen V; Hagens P; Cohen D; Cooney E; Noviello S; Hughes E, 2013, '1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s570 - s571, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/s0168-8278(13)61417-8

Jacobson I; Dore GJ; Foster GR; Fried MW; Radu M; Rafalskiy VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Kalmeijer R; Beumont-Mauviel M, 2013, '1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s574, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/s0168-8278(13)61424-5

Grebely J; Page K; Sacks-Davis R; van der Loeff MS; Rice TM; Bruneau J; Morris MD; Hajarizadeh B; Amin J; Cox AL; Kim AY; McGovern BH; George J; Shoukry N; Lauer G; Maher L; Lloyd AR; Hellard M; Dore GJ; Prins M; Group OBOTIS, 2013, '461 SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION IS ASSOCIATED WITH FEMALE SEX, IL28B GENOTYPE AND HCV GENOTYPE 1 INFECTION', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s189, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/s0168-8278(13)60463-8

Holmes JA; Bonanzinga S; Roberts SK; Sievert W; Dore GJ; McCaughan G; Crawford DH; Cheng WS; Weltman MD; Matthews G; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Thompson AJ, 2013, '462 THE ASSOCIATION BETWEEN HAEMOGLOBIN DECLINE AND SVR IS INDEPENDENT OF ITPA GENOTYPE DURING PEG-INTERFERON PLUS RIBAVIRIN THERAPY FOR HCV-1: ANALYSIS FROM THE CHARIOT STUDY', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s189 - s190, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/s0168-8278(13)60464-x

Kitson MT; Dore GJ; George J; Button P; McCaughan GW; Crawford DH; Sievert W; Weltman MD; Cheng WS; Roberts SK; Group CHARIOTS, 2013, '466 INTERLEUKIN-28B rs12979860 C ALLELE IS PROTECTIVE AGAINST ADVANCED FIBROSIS IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s191, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/s0168-8278(13)60468-7

Alavi M; Raffa JD; Deans GD; Lai C; Krajden M; Dore GJ; Tyndall MW; Grebely J, 2013, '785 CONTINUED LOW UPTAKE OF TREATMENT FOR HCV IN A LARGE COMMUNITY-BASED COHORT OF INNER CITY RESIDENTS', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s319 - s320, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/s0168-8278(13)60787-4

Berg T; Shiffman ML; Zeuzem S; Berg CP; de Figueiredo- Mendes C; Dore GJ; Ferraz ML; Mendes-Corrêa MC; Lima MP; Parise E; Rios AMP; Reuter T; Sanyal AJ; Shafran SD; Hohmann M; Tatsch F; Cheinquer H; Group OBOTN-CORES, 2013, '792 48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s323, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/s0168-8278(13)60794-1

Doyle JS; Deterding K; Grebely J; Wedemeyer H; Davis RS; Matthews G; Rice T; Morris M; McGovern BH; Kim AY; Bruneau J; Lloyd AR; Page K; Manns M; Hellard ME; Dore GJ; Group IS, 2013, '811 RESPONSE TO TREATMENT FOLLOWING RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s332, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/s0168-8278(13)60813-2

Aspinall E; Grebely J; Hutchinson S; Innes H; Walter S; Amin J; Yu A; Goldberg D; Krajden M; Law M; Dore G; Law M, 2013, '965 TRENDS IN MORTALITY AFTER DIAGNOSIS OF HEPATITIS C INFECTION – AN INTERNATIONAL COMPARISON', in Journal of Hepatology, Elsevier, NETHERLANDS, Amsterdam, pp. s397 - s398, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/s0168-8278(13)60967-8

Jacka B; Lamoury F; Simmonds P; Dore GJ; Grebely J; Applegate T, 2013, 'SEQUENCING THE HEPATITIS C VIRUS: A SYSTEMATIC REVIEW', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, pp. S471 - S472, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), NETHERLANDS, Amsterdam, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)61160-5

Cheinquer H; Shiffman ML; Zeuzem S; Berg CP; Berg T; Figueiredo-Mendes CG; Dore GJ; Ferraz ML; Mendes-Correa MC; Lima MP; Parise ER; Perez AM; Reuter T; Sanyal AJ; Shafran SD; Hohmann M; Tatsch F, 2012, 'The outcome of 24 vs. 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 271A - 272A, presented at 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 09 November 2012 - 13 November 2012

Dore GJ; Lawitz E; Hezode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Albert T; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey DG; Pol S; Harley H; George J; Fung S; de Ledinghen V; Hagens P; Cohen DS; Hughes EA; Cooney EL, 2012, 'Twelve- or 16-Week Treatment With Daclatasvir Combined With Peginterferon Alfa and Ribavirin for Hepatitis C Virus Genotype 2 or 3 Infection: Command GT2/3 Study', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 558A - 559A, presented at 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 09 November 2012 - 13 November 2012

Roberts S; Mitchell J; Leung RC; Booth D; Mccaughan G; Crawford DH; Thompson A; Sievert W; Dore G; George J, 2012, 'The distribution of polymorphisms in the IL28B gene in previously untreated Australian patients with genotype 1 CHC: the predict study', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY-BLACKWELL, pp. 178 - 178, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000308642600361&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kitson MT; Dore GJ; Button P; McCaughan G; Crawford D; Sievert W; Weltman M; Cheng W; Roberts SK, 2012, '1126 VITAMIN D STATUS IS ASSOCIATED WITH COMPLETE EVR BUT NOT SVR IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT', in Journal of Hepatology, Elsevier, SPAIN, Barcelona, pp. s443 - s444, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012, http://dx.doi.org/10.1016/s0168-8278(12)61138-6

Grebely J; Feld JJ; Applegate T; Matthews G; Hellard M; Sherker A; Petoumenos K; Shaw I; Yeung B; Kaldor JM; Cherepanov V; Bruneau J; Lloyd A; Shoukry N; Dore G, 2012, '889 PLASMA IP10 LEVEL PREDICTS SPONTANEOUS CLEARANCE IN ACUTE HCV INFECTION', in Journal of Hepatology, Elsevier, SPAIN, Barcelona, pp. s346, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012, http://dx.doi.org/10.1016/s0168-8278(12)60901-5

Grebely J; Dore GJ; van der Loeff MS; Rice T; Cox AL; Bruneau J; Kim AY; George J; Maher L; Lloyd AR; Hellard M; Page K; Prins M, 2012, '894 FEMALE SEX AND VARIATIONS IN IL28B ARE INDEPENDENTLY ASSOCIATED WITH SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION', in Journal of Hepatology, Elsevier, SPAIN, Barcelona, pp. s348, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012, http://dx.doi.org/10.1016/s0168-8278(12)60906-4

Kitson MT; Dore GJ; Button P; McCaughan G; Crawford D; Sievert W; Weltman M; Cheng W; Roberts SK, 2012, '901 VITAMIN D STATUS AND LIVER HISTOLOGY IN CHRONIC HEPATITIS C GENOTYPE 1 INFECTION: ANALYSIS OF THE AUSTRALASIAN CHARIOT STUDY COHORT', in Journal of Hepatology, Elsevier, SPAIN, Barcelona, pp. s350 - s351, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), SPAIN, Barcelona, 18 April 2012 - 22 April 2012, http://dx.doi.org/10.1016/s0168-8278(12)60913-1

Fried M; Buti M; Dore GJ; Flisiak R; Ferenci P; Jacobson IM; Marcellin P; Manns MP; Nikitin I; Poordad FF; Sherman M; Zeuzem S; Lenz O; Peeters M; Sekar V; De Smedt G, 2011, 'TMC435 IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1 PATIENTS: FINAL ANALYSIS OF THE PILLAR PHASE IIB STUDY', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1429A - 1429A, presented at 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 04 November 2011 - 08 November 2011

Ali RJ; Bowden S; Avihingsanon A; Lewin SR; Ruxrungtham K; Locarnini S; Sasadeusz J; Dore GJ; Matthews G, 2011, 'CHANGES IN QUANTITATIVE HBSAG AND HBEAG PREDICT HBV TREATMENT RESPONSE IN HBV/HIV COINFECTED INDIVIDUALS ON TENOFOVIR BASED HAART IN THAILAND', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1081A - 1081A, presented at 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 04 November 2011 - 08 November 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000295578003739&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Matthews G; Applegate TL; Tschochner M; Plauzolles A; Mallal SA; Grebely J; Hellard M; Lloyd AR; Kaldor JM; Dore GJ; Gaudieri S, 2011, 'ULTRA DEEP SEQUENCING ANALYSIS OF TREATMENT NAIVE INDIVIDUALS WITH RECENTLY ACQUIRED HEPATITIS C INFECTION DEMONSTRATES WIDESPREAD AMINO ACID VARIATION AT KEY PROTEASE AND POLYMERASE SITES OCCURRING AT LOW FREQUENCY', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 1343A - 1344A, presented at 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), CA, San Francisco, 04 November 2011 - 08 November 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000295578004555&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Applegate T; Gaudieri S; Pham S; White P; Grebely J; Hellard M; Suppiah V; George J; Lloyd A; Dore G; Matthews GV, 2011, 'Impact of host and viral characteristics on treatment outcome within hepatitis C transmission clusters in HIV-positive individuals with recently acquired HCV', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Los Cabos, MEXICO, pp. A87 - A87, presented at International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Los Cabos, MEXICO, 07 June 2011 - 11 June 2011, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294375700092&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Gaudieri S; Applegate T; Tschochner M; Plauzolles A; Pfafferott K; Lucas M; Diepolder H; Ulsenheimer A; Mallal S; Grebely J; Hellard M; Lloyd A; Kaldor J; Dore G; Matthews GV, 2011, 'Signature resistance mutations to directly acting antiviral agents occur at low prevalence in treatment-naive subjects with recently acquired hepatitis C infection', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, Los Cabos, MEXICO, pp. A86 - A86, presented at International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Los Cabos, MEXICO, 07 June 2011 - 11 June 2011, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294375700091&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ali RJ; Roberts SK; Ray J; Sievert W; McCaughan G; Weltman M; Crawford D; Cheng W; Rawlinson W; Thommes J; Rizkalla B; Yoshihara M; Dore GJ; Matthews GV, 2011, 'EARLY ON-TREATMENT PLASMA RIBAVIRIN CONCENTRATIONS ARE ASSOCIATED WITH ON-TREATMENT ANAEMIA AND TREATMENT OUTCOME IN CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S161 - S161, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)60403-0

Grebely J; Matthews GV; Hellard M; Suppiah V; Petoumenos K; Applegate T; Yeung B; Rawlinson W; Feld J; Lloyd AR; Booth D; Kaldor JM; George J; Dore GJ, 2011, 'IL28B GENOTYPE HAS VARIABLE INFLUENCE ON EARLY VIRAL KINETICS, BUT NO INFLUENCE ON SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S524 - S524, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)61330-5

Grebely J; Alavi M; Haber P; Day C; Matthews GV; van Beek I; Walsh N; Yeung B; Petoumenos K; Dolan K; Spelman T; Kaldor JM; Dore GJ; Hellard M, 2011, 'IMPACT OF TREATMENT ON INJECTING DRUG USE BEHAVIORS DURING RECENT HCV INFECTION: THE ATAHC STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S174 - S174, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)60431-5

Feld JJ; Grebely J; Applegate T; Matthews GV; Hellard M; Suppiah V; Sherker A; Petoumenos K; Shaw I; Yeung B; Rawlinson W; Booth D; Kaldor JM; Lloyd AR; Dore GJ, 2011, 'IP-10 IS ASSOCIATED WITH EARLY VIRAL KINETICS, BUT NOT SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S455 - S455, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)61154-9

Gaudieri S; Applegate T; Tshochner M; Plauzolles A; Pfafferott K; Lucas M; Diepolder H; Ulsenheimer A; Mallal S; Grebely J; Hellard M; Lloyd A; Kaldor J; Dore G; Matthews G, 2011, 'SIGNATURE RESISTANCE MUTATIONS TO DIRECTLY ACTING ANTIVIRAL AGENTS OCCUR AT LOW PREVALENCE IN TREATMENT NAIVE SUBJECTS WITH RECENTLY ACQUIRED HEPATITIS C INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER, GERMANY, Berlin, pp. S184 - S185, presented at 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), GERMANY, Berlin, 30 March 2011 - 03 April 2011, http://dx.doi.org/10.1016/S0168-8278(11)60455-8

Applegate T; Gaudieri S; Pham S; White P; Grebely J; Hellard M; Suppiah V; George J; Lloyd A; Dore G; Matthews GV, 2011, 'Impact of host and viral characteristics on treatment outcome within hepatitis C transmission clusters in HIV-positive individuals with recently acquired HCV', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, pp. A87 - A87, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000687677600071&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Gaudieri S; Applegate T; Tschochner M; Plauzolles A; Pfafferott K; Lucas M; Diepolder H; Ulsenheimer A; Mallal S; Grebely J; Hellard M; Lloyd A; Kaldor J; Dore G; Matthews GV, 2011, 'Signature resistance mutations to directly acting antiviral agents occur at low prevalence in treatment-naive subjects with recently acquired hepatitis C infection', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, pp. A86 - A86, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000687677600070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Matthews GV; Alavi M; Grebely J; Petoumenos K; Yeung B; Hellard M; Lloyd A; van Beek I; Kaldor J; Haber P; Dore GJ, 2010, 'Depression prior to and during treatment for recent hepatitis C virus (HCV) infection among HCV and HCV/HIV participants in the ATAHC study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A21 - A21, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431200041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Matthews GV; Alavi M; Grebely J; Petoumenos K; Yeung B; Hellard M; Lloyd A; van Beek I; Kaldor J; Haber P; Dore GJ, 2010, 'Depression prior to and during treatment for recent hepatitis C virus (HCV) infection among HCV and HCV/HIV participants in the ATAHC study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A21 - A21, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431500027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Audsley J; Seaberg E; Sasadeusz J; Matthews GV; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson R; Hwang HS; Littlejohn M; Dore GJ; Locarnini S; Thio CL; Lewin SR, 2010, 'Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A53 - A53, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431200068&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Audsley J; Seaberg E; Sasadeusz J; Matthews GV; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson R; Hwang HS; Littlejohn M; Dore GJ; Locarnini S; Thio CL; Lewin SR, 2010, 'Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A53 - A53, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431500054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Fried MW; Buti M; Dore GJ; Ferenci P; Jacobson I; Marcellin P; Zeuzem S; Lenz O; Peeters M; Sekar VJ; De Smedt G, 2010, 'EFFICACY AND SAFETY OF TMC435 IN COMBINATION WITH PEGINTERFERON alpha-2A AND RIBAVIRIN IN TREATMENT-NAiVE GENOTYPE-1 HCV PATIENTS: 24-WEEK INTERIM RESULTS FROM THE PILLAR STUDY', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 403A - 404A, presented at 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 29 October 2010 - 02 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000288775600168&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Roberts SK; Ferenci P; Yoshihara M; Crawford DH; Sieverf W; McCaughan GW; Cheng W; Weltman M; Rawlinson WD; McCloud PI; Rizkalla B; Dore GJ, 2010, 'NON-SVR TO PEGINTERFERON ALFA-2A THERAPY AND RIBAVIRIN IS SRONGLY PREDICTED BY BASELINE FACTORS AND WEEK 8 ON-TREATMENT VIRAL LOAD IN HCV GENOTYPE (GT) 1 PATIENTS: NEW INSIGHTS FROM CART ANALYSIS OF THE CHARIOT STUDY', in HEPATOLOGY, WILEY-BLACKWELL, MA, Boston, pp. 801A - 802A, presented at 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 29 October 2010 - 02 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000288775601314&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Marcellin P; Reddy KR; Roberts SK; Jensen DM; Harrison SA; Hadziyannis SJ; Dore G; Diago M; Weltman MD; Solsky J; Tietz A; Rizzetto M, 2010, 'Peginterferon Alfa-2a (40KD) Has a Wide Safety Margin in Patients Infected With Hepatitis C Virus Genotype 1: Pooled Data From Four Randomized Multicenter Studies', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, pp. S844 - S844, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000475844804188&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore G, 2010, 'DIFFERENCES IN EARLY VIROLOGICAL DECLINE IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV SUGGEST A POTENTIAL BENEFIT FOR THE USE OF RIBAVIRIN', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, pp. S28 - S28, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 14 April 2010 - 18 April 2010, http://www.journal-of-hepatology.eu/article/S0168-8278(10)60062-1/abstract

Grebely J; Dore GJ; van der Loeff MS; Cox AL; Bruneau J; Kim AY; Lloyd AR; Hellard M; Page K; Prins M, 2010, 'FACTORS ASSOCIATED WITH SPONTANEOUS CLEARANCE DURING ACUTE HEPATITIS C VIRUS INFECTION', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S411 - S411, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 14 April 2010 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)61064-1

Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore GJ, 2010, 'WEEK 4 HCV RNA IS THE OPTIMAL PREDICTOR OF SVR IN BOTH HIV POSITIVE AND NEGATIVE SUBJECTS WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, AUSTRIA, Vienna, pp. S116 - S116, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 14 April 2010 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)60278-4

McCaughan GW; Roberts SK; Weltman M; Crawford DH; Sievert W; Cheng W; Rawlinson W; Yoshihara M; McCloud PI; Rizkalla B; Dore GJ, 2009, 'ADVANCED FIBROSIS IN GENOTYPE 1 HCV INFECTED PATIENTS RECEIVING ANTIVIRAL THERAPY IS ASSOCIATED WITH VIROLOGIC RELAPSE INDEPENDENT OF RAPID (RVR) AND EARLY (EVR) VIROLOGIC RESPONSE', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1027A - 1028A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001564&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Weltman M; Dore GJ; Sievert W; McCaughan GW; Crawford DH; Cheng W; Rawlinson W; Yashihara M; McCloud PI; Rizkalla B; Roberts SK, 2009, 'BASELINE AND ONTREATMENT PREDICTORS OF SVR TO PEGINTERFERON ALFA-2A THERAPY AND RIBAVIRIN IN HCV GENOTYPE (GT) 1 TREATMENT NAIVE PATIENTS: NEW INSIGHTS FROM THE CHARIOT STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1033A - 1034A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001574&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Matthews G; Grebely J; Pham ST; Hellard M; Marks P; Rawlinson W; Kaldor J; Lloyd AR; White PA; Dore GJ, 2009, 'EPIDEMIOLOGY OF RECENTLY ACQUIRED HEPATITIS C VIRUS (HCV) INFECTION IN HCV AND HCV/HIV INFECTED PARTICIPANTS IN THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 668A - 668A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000775&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Iser DM; Boyd AJ; Avihingsanon A; Thompson AL; Nguyen T; Matthews G; Bowden S; Locarnini S; Slavin J; Desmond PV; Dore GJ; Ruxrungtham K; Lewin SR, 2009, 'NO INCREASE IN INTRAHEPATIC MONONUCLEAR CELL OR STELLATE CELL ACTIVATION IN HIV-HBV CO-INFECTED INDIVIDUALS WITH ADVANCED HIV AND MILD LIVER DISEASE', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 993A - 994A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001493&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Marcellin P; Jensen DM; Roberts SK; Hadziyannis SJ; Dore GJ; Diago M; Weltman M; McCaughan GW; Cheng W; Crawford DH; Sievert W; Rawlinson W; Solsky J; Tietz A; Rizzetto M, 2009, 'PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) HAS A WIDE SAFETY MARGIN IN COMBINATION WITH RIBAVIRIN (RBV) 1000/1200 MG/DAY IN PATIENTS INFECTED WITH HCV GENOTYPE 1: POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED MULTICENTER STUDIES', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1030A - 1031A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001569&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Roberts SK; Ngu MC; Strasser SI; George J; Dore GJ; Locarnini S; Sasadeusz J; Sievert W; Peschell KJ; Mitchell K; Elsome AM, 2009, 'PREVALENCE AND NATURE OF VIRAL MUTATIONS IN CHRONIC HEPATITIS B (CHB) PATIENTS ON ORAL ANTIVIRAL THERAPY (AVT): THE CHARM STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 488A - 489A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000390&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sievert W; Dore GJ; McCaughan GW; Yoshihara M; Crawford DH; Cheng W; Weltman M; Rawlinson W; Rizkalla B; McCloud PI; Roberts SK, 2009, 'SIGNIFICANT HEMOGLOBIN (HB) DECLINE DURING PEGYLATED INTERFERON AND RIBAVIRIN THERAPY IN HCV GENOTYPE 1 IS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR): AN ANALYSIS FROM THE CHARIOT STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 1020A - 1021A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456001552&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan GW; White PA; Ffrench RA; Rawlinson W; Lloyd AR; Kaldor J, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 723A - 723A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 30 October 2009 - 03 November 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000887&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page